Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSVMT) in golden syrian hamster

Ke, Yong; Zhang, En; Guo, Jianming; Zhang, Xiaoxiao; Wang, Lei; Chen, Duo; Fang, Xinkui; Zhu, Jianwei; Li, Feng; Sun, Tao; Zhang, Baohong

doi:10.1016/j.apsb.2023.08.023

Cited by 1 publication

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current intramuscular COVID-19 vaccines struggle to induce respiratory mucosal immunity, highlighting the need for strategies to enhance local mucosal immunity post-intramuscular immunization. 22,76,77 Several approaches have entered clinical trials and have been approved for urgent use. However, some vaccines trigger antiviral immunity against the vector backbone, potentially hindering the effectiveness of repeated vaccinations.…”

Section: Discussionmentioning

confidence: 99%

“…Most vaccines are administered intramuscularly, and establishing mucosal immunity is crucial, especially because COVID-19 is primarily a respiratory disease. Current intramuscular COVID-19 vaccines struggle to induce respiratory mucosal immunity, highlighting the need for strategies to enhance local mucosal immunity post-intramuscular immunization. ,, Several approaches have entered clinical trials and have been approved for urgent use. However, some vaccines trigger antiviral immunity against the vector backbone, potentially hindering the effectiveness of repeated vaccinations. , Our data suggest that the EV-RBD vaccine is a safe and effective mucosal vaccine capable of inducing robust mucosal immunity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Virus-Mimetic Extracellular-Vesicle Vaccine Boosts Systemic and Mucosal Immunity via Immune Recruitment

Li,

Xing,

Meng

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Mucosal vaccines can prevent viruses from infecting the respiratory mucosa, rather than only curtailing infection and protecting against the development of disease symptoms. The SARS-CoV-2 spike receptor-binding domain (RBD) is a compelling vaccine target but is undermined by suboptimal mucosal immunogenicity. Here, we report a SARS-CoV-2-mimetic extracellular-vesicle vaccine developed using genetic engineering and dendritic cell membrane budding. After mucosal immunization, the vaccine recruits antigen-presenting cells rapidly initiating a strong innate immune response. Notably, it obviates the need for adjuvants and can induce germinal center formation through both intramuscular and intratracheal vaccination. It not only elicits high levels of RBDspecific antibodies but also stimulates extensive cellular immunity in the respiratory mucosa. A sequential immunization strategy, starting with an intramuscular injection followed by an intratracheal booster, significantly bolsters mucosal immunity with high levels of IgA and tissue-resident memory T cell responses, thereby establishing a formidable defense against pseudovirus infection.

show abstract

Section: Discussionmentioning

confidence: 99%